Skip to main content
AstraZeneca PLC logo

AstraZeneca PLC — Investor Relations & Filings

Ticker · AZN ISIN · GB0009895292 LEI · PY6ZZQWO2IZFZC3IOL08 IL Manufacturing
Open in API
Filings indexed 3,304 across all filing types
Latest filing 2024-12-24 Regulatory Filings
Country GB United Kingdom
Listing IL AZN

About AstraZeneca PLC

https://www.astrazeneca.com/

AstraZeneca PLC is a global, science-led biopharmaceutical company that focuses on the discovery, development, and commercialization of prescription medicines. The company's portfolio is concentrated on several main therapy areas, including Oncology; Cardiovascular, Renal & Metabolism; and Respiratory & Immunology. AstraZeneca is committed to advancing healthcare through a robust research and development pipeline, aiming to deliver innovative medicines that address significant unmet medical needs for millions of patients worldwide. The company leverages scientific innovation to transform the future of healthcare and improve patient outcomes.

Recent filings

Filing Released Lang Actions
Dato-DXd NSQ NSCLC application withdrawn in EU
Regulatory Filings Classification · 1% confidence The document begins with 'RNS Number : 1961R' and contains standard regulatory boilerplate language from 'RNS, the news service of the London Stock Exchange' and mentions compliance with the 'Financial Conduct Authority'. The content is a specific announcement regarding the voluntary withdrawal of a Marketing Authorisation Application (MAA) in the EU for a drug (datopotamab deruxtecan). This type of immediate, material corporate news disseminated via the official exchange news service strongly indicates a regulatory announcement. Since it is not a full financial report (10-K, IR), an earnings release (ER), or a proxy statement (DEF 14A), and it is a specific regulatory update, the most appropriate classification is Regulatory Filings (RNS), which serves as the general category for such announcements not covered by more specific codes.
2024-12-24 English
TAGRISSO APPROVED IN EU BASED ON LAURA TRIAL
Foreign Filer Report
2024-12-23 English
Tagrisso approved in EU based on LAURA trial
Legal Proceedings Report Classification · 1% confidence The document is clearly identified as an RNS announcement by the header 'RNS Number : 0214R' and the concluding statement: 'This information is provided by RNS, the news service of the London Stock Exchange.' The content details a significant regulatory/business event: the EU approval of AstraZeneca's drug Tagrisso based on Phase III trial results. This type of immediate, material corporate news release, especially one originating from the RNS system, falls under the general category for regulatory announcements that are not specifically covered by other detailed forms (like 10-K, ER, or DIV). Since it is a general regulatory announcement and not a specific report type like an Earnings Release (ER) or a formal Annual Report (10-K), the most appropriate classification is Regulatory Filings (RNS). The document length is substantial (13,251 chars), so it is the announcement itself, not just a notice of publication (RPA).
2024-12-23 English
DIRECTORATE CHANGE
Foreign Filer Report
2024-12-16 English
Directorate Change
Board/Management Information Classification · 1% confidence The document is a formal announcement released via RNS (RNS Number: 1206Q) detailing the appointment of two new Non-Executive Directors to the AstraZeneca PLC Board, including their effective dates and biographical details. This directly relates to changes in the company's governing body. According to the definitions, 'Board/Management Information' (MANG) covers the 'Announcement of changes in the company's board of directors or senior management.' Although it is distributed via RNS, the specific content is MANG, which takes precedence over the general RNS fallback.
2024-12-16 English
IMFINZI APPROVED IN US FOR LIMITED-STAGE SCLC
Foreign Filer Report
2024-12-05 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.